|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inhibition of α-glucosidase is one of the alternatives approach to control postprandial hyperglycemia by, resulting in the delay of the carbohydrate digestion of absorbable monosaccharides.
|
31702433 |
2020 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Delaying the absorption of glucose through α-glucosidase enzymes inhibition is one of the therapeutic approaches in the management of Type 2 diabetes, which can reduce the incidence of postprandial hyperglycemia.
|
31553294 |
2020 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
α-Glucosidase is an important enzyme in human intestine, and inhibition of its activity can lower blood sugar levels to effectively prevent hyperglycaemia induced tissue damage.
|
31816382 |
2020 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The inhibition of α-glucosidase activity is a prospective approach to prevent postprandial hyperglycemia.
|
31765755 |
2019 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
α-glucosidase inhibitors compete with the α-glucosidase enzyme activity, which helps to reduce the conversion of carbohydrates into glucose and thereby control the postprandial hyperglycemia incidence.
|
31808390 |
2019 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Functional foods that inhibit α-amylase and α-glucosidase activity are effective for regulating the blood glucose level and preventing hyperglycemia.
|
31613007 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
5,7-Dimethoxy-3-(2'-hydroxybenzyl)-4-chromanone inhibits α-glucosidase in vitro and alleviates postprandial hyperglycemia in diabetic mice.
|
31550448 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, a hypoglycemia test also verified that these α-glucosidase inhibitors had the potential to reduce post-prandial hyperglycaemia in C57BL/6 mice.
|
30865735 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have demonstrated that α-glucosidase inhibitor improves postprandial hyperglycemia and then reduces the risk of developing type 2 diabetes in patients.
|
31317269 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of α-amylase and α-glucosidase by specified synthetic compounds during the digestion of starch helps control post-prandial hyperglycemia and could represent a potential therapy for type II diabetes mellitus.
|
31242688 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-glucosidase inhibition is thus the ideal target to prevent postprandial hyperglycemia.
|
30682840 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acarbose is an α-glucosidase inhibitor that suppresses postprandial hyperglycemia, however, the cardiovascular protection of acarbose has still remained controversial.
|
31541678 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pheophorbide A from Gelidium amansii improves postprandial hyperglycemia in diabetic mice through α-glucosidase inhibition.
|
30648298 |
2019 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that PB2 is useful for protection against hyperglycemia through inhibiting the activity of α-glucosidase.
|
30188554 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy of Alpha Glucosidase Inhibitor from Marine Actinobacterium in the Control of Postprandial Hyperglycaemia in Streptozotocin (STZ) Induced Diabetic Male Albino Wister Rats.
|
29755552 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The α-amylase and α-glucosidase inhibitory activities of UIOPS-1 were significantly increased after digestion indicating a good control of postprandial hyperglycemia (P<0.001).
|
29389616 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study provides new insight into the potential application of Lu'an GuaPian green tea as a functional food ingredient to regulate postprandial hyperglycemia through inhibition of α-glucosidase/α-amylase by FGs, particularly the mono- and di- glycosides of kaempferol.
|
29989631 |
2018 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
UIOPC also showed significant inhibitory capacity on α-amylase and α-glucosidase than UIOPS (P < 0.05), suggesting a good regulation of the postprandial hyperglycemia.
|
29689356 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inhibition of α-glucosidase and α-amylase is a clinical strategy for the treatment of type II diabetes, and herbal medicines have been reported to credibly alleviate hyperglycemia.
|
30189596 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study has identified two novel and active α-glucosidase inhibitory peptides that could resist GIT digestion and therefore, have the potential to retard postprandial hyperglycemia in diabetic patients.
|
30096627 |
2018 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The inhibition of α-glucosidase, a key carbohydrate hydrolyzing enzyme, could serve as one of the effective methodology in both preventing and treating diabetes through controlling the postprandial glucose levels and suppressing postprandial hyperglycemia.
|
29421697 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Scopoletin inhibits α-glucosidase in vitro and alleviates postprandial hyperglycemia in mice with diabetes.
|
30031794 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of α-glucosidase is an effective strategy for controlling the post-prandial hyperglycemia in diabetic patients.
|
30118991 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of α-glucosidase is an effective strategy for controlling post-prandial hyperglycemia in diabetic patients.
|
29223804 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-glucosidase is involved in the hydrolyses of disaccharide into monosaccharides and results in hyperglycemia.
|
29885400 |
2018 |